EMA Authorised: Brilique (ticagrelor) — AstraZeneca AB

View source ↗

Summary

Brilique (ticagrelor) has been authorised for use in the European Union for indications related to Acute Coronary Syndrome and peripheral vascular diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Peripheral Vascular Diseases

Drugs mentioned

• Brilique (ticagrelor)

Snippet

Status: Authorised. Therapeutic area: Peripheral Vascular Diseases;Acute Coronary Syndrome. MAH: AstraZeneca AB. Decision date: 13/08/2026